FDA Approves New and Updated Indications for Temozolomide Under Project Renewal

On September 14, the US Food and Drug Administration (FDA) approved updated labeling for temozolomide under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date. 

For more information read the FDA announcement. 

Posted 9/21/2023